Enlarge / Vials of the Pfizer COVID-19 vaccine. (credit: SOPA images)
Pfizer and BioNTech will request authorization from the US Food and Drug Administration this week for their three-dose COVID-19 vaccine for children ages 6 months to under 5 years, the companies announced this morning.
Top-line clinical trial results indicate that the vaccine series is safe and produces a strong immune response against the pandemic virus, according to the companies.
"The study suggests that a low 3-[microgram] dose of our vaccine… provides young children with a high level of protection against the recent COVID-19 strains," BioNTech CEO Ugur Sahin said in a statement.
Read 9 remaining paragraphs | Comments